National Lipid Association asks members to complete survey on PCSK9 inhibitors

The National Lipid Association (NLA) is asking members to complete an online survey regarding challenges patients face in getting access to proprotein convertase subtilisin kexin type 9 (PCSK9) inhibitors.

The NLA said prescribers and non-prescribers could complete the survey by Sept. 30.

The FDA has approved two PCSK9 inhibitors: alirocumab (Praluent, Regeneron Pharmaceuticals and Sanofi Aventis) and evolocumab (Repatha, Amgen).

The injectable medications have been shown to lower low-density lipoprotein cholesterol, but trials are ongoing to determine if the drugs have an effect on cardiovascular mortality and morbidity.

Sales of the medications, which cost more than $14,000 per year, have fallen short of expectations since they were approved last summer.